Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Clene Shares Fall Despite Multiple Sclerosis Candidate Showing Neurological Improvements

Published 15/08/2022, 14:04
Updated 15/08/2022, 14:40
© Reuters.  Clene Shares Fall Despite Multiple Sclerosis Candidate Showing Neurological Improvements

© Reuters. Clene Shares Fall Despite Multiple Sclerosis Candidate Showing Neurological Improvements

  • Clene Inc (NASDAQ: CLNN) has announced topline results from the Phase 2 VISIONARY-MS trial of CNM-Au, an investigational gold nanocrystal suspension, in stable relapsing-remitting multiple sclerosis.
  • As announced in February, the trial was stopped prematurely due to COVID-19 pandemic operational challenges, limiting enrollment to 73 out of the 150 planned participants.
  • CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity and modified Multiple Sclerosis Functional Composite compared to placebo over 48 weeks in the mITT population.
  • Also Read: Clene's CNM-Au8 Shows Decreased Mortality Amyotrophic Lateral Sclerosis Patients.
  • Consistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers.
  • CNM-Au8 treatment was well-tolerated, and there were no significant safety findings reported.
  • Rob Etherington, CEO & president, added, "we also await additional evidence of clinical efficacy from the HEALEY ALS Platform Trial, which is expected to report topline data later this quarter."
  • Clene ended Q2 with cash, cash equivalents, and marketable investment securities of $26.3 million and entered into a $3.0 million loan facility to support the development of a commercial manufacturing facility.
  • Price Action: CLNN shares are down 8.41% at $3.16 during the premarket session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.